Atsushi Ohtsu

Atsushi Ohtsu's AcademicInfluence.com Rankings

Atsushi Ohtsu

Philosophy

#7095

World Rank

#10256

Historical Rank

Logic

#4172

World Rank

#5432

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Atsushi Ohtsu's Degrees

Doctorate Medicine University of Tokyo
PhD Medicine University of Tokyo

Why Is Atsushi Ohtsu Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Atsushi Ohtsu's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (2010) (5682)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. (2014) (1712)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial (2018) (1140)
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. (2015) (886)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (2018) (791)
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. (2009) (575)
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. (2014) (499)
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. (2011) (477)
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. (2012) (452)
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. (2013) (425)
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). (2003) (418)
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. (1999) (395)
Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites (2004) (375)
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. (2003) (344)
Guidelines for diagnosis and treatment of carcinoma of the esophagus (2008) (340)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. (2017) (325)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. (2017) (302)
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). (2011) (291)
Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. (2003) (282)
Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. (1999) (281)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. (2012) (279)
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 (2007) (269)
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer (2003) (266)
UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer (2004) (262)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. (2018) (261)
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. (2006) (243)
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. (2002) (238)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. (2017) (238)
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. (2004) (224)
Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. (2002) (222)
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. (2010) (207)
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. (2003) (202)
Chemotherapy for metastatic gastric cancer: past, present, and future (2008) (178)
Disparities in gastric cancer chemotherapy between the East and West. (2006) (169)
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients (2017) (168)
Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population (2004) (159)
Detection of point mutations in the K‐ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma (1994) (152)
Efficacy of Preventive Endoscopic Balloon Dilation for Esophageal Stricture After Endoscopic Resection (2011) (148)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (147)
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. (1997) (145)
Acetaldehyde production by non‐pathogenic Neisseria in human oral microflora: Implications for carcinogenesis in upper aerodigestive tract (2000) (142)
Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. (2001) (140)
Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors (2010) (139)
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. (2006) (134)
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma (2015) (134)
Local recurrence of squamous-cell carcinoma of the esophagus after EMR. (2005) (133)
An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. (1998) (129)
AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). (2010) (122)
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. (2011) (121)
Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma (2004) (118)
Gastric Cancer Working Group report. (2010) (117)
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. (2009) (117)
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer (2019) (112)
Association of aldehyde dehydrogenase 2gene polymorphism with multiple oesophageal dysplasia in head and neck cancer patients (2000) (111)
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. (1998) (107)
Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus (2003) (104)
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. (2005) (101)
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. (2018) (99)
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. (2003) (99)
OPTICAL/DIGITAL CHROMOENDOSCOPY DURING COLONOSCOPY USING NARROW‐BAND IMAGING SYSTEM (2005) (98)
Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region. (2005) (97)
Usefulness of endoscopic radial incision and cutting method for refractory esophagogastric anastomotic stricture (with video). (2012) (97)
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. (2004) (96)
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. (2019) (96)
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study (2011) (96)
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients (2015) (95)
Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients (2003) (95)
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations (2014) (94)
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. (2017) (91)
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. (2004) (91)
Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer. (2002) (91)
Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2007 edition: part I Edited by the Japan Esophageal Society (2008) (89)
Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. (2008) (89)
Detection of K‐ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas (1997) (88)
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer (2019) (88)
mTOR as a therapeutic target in patients with gastric cancer (2012) (87)
The histological basis of detection of adenoma and cancer in the colon by autofluorescence endoscopic imaging. (1999) (87)
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). (2013) (86)
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours (2012) (86)
A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). (2016) (84)
Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor (2011) (83)
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors (2014) (82)
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan (2003) (81)
Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. (2009) (81)
Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study. (2010) (80)
Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: A phase II study (2012) (80)
Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer. (2011) (80)
Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma (2016) (79)
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer (2015) (77)
Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors (2009) (77)
Haplotype structures of the UGT1A gene complex in a Japanese population (2006) (76)
A Retrospective Study of Definitive Chemoradiotherapy for Elderly Patients With Esophageal Cancer (2007) (74)
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. (2013) (73)
Clinicopathological differences between colonic and rectal carcinomas: are they based on the same mechanism of carcinogenesis? (1999) (73)
Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. (2005) (73)
Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202) (2008) (73)
Endoscopic mucosal resection in the stomach using the insulated-tip needle-knife. (2005) (72)
Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). (1994) (71)
Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer (2008) (69)
EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. (2003) (69)
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer (2016) (69)
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. (1994) (69)
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer (2019) (67)
Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205) (2017) (67)
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. (2002) (65)
Current status and future prospects of chemotherapy for metastatic gastric cancer: a review (2005) (65)
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. (2010) (64)
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer (2017) (63)
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate (2010) (63)
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. (2016) (62)
Long-term results of salvage photodynamic therapy for patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. (2011) (61)
Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. (2016) (60)
Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. (2003) (58)
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients (2010) (57)
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study (2016) (57)
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma† (2016) (57)
Genetic variations and haplotypes of UGT1A4 in a Japanese population. (2005) (56)
Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer (2012) (55)
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences (2007) (54)
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. (2004) (53)
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. (2010) (53)
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (2021) (52)
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. (2014) (51)
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data (2017) (51)
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors (2011) (50)
Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. (2012) (50)
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (50)
Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. (2001) (49)
KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab (2011) (47)
Functional analysis of four naturally occurring variants of human constitutive androstane receptor. (2005) (47)
FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2) (2005) (47)
Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck. (2012) (47)
Quality of life in the trastuzumab for gastric cancer trial. (2014) (45)
Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. (2006) (45)
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). (2016) (44)
Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit (2013) (44)
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma (2016) (44)
Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer. (2003) (44)
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. (2013) (42)
Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae (1999) (42)
Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. (1995) (42)
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer (2006) (42)
Patients' perception of the usefulness of a question prompt sheet for advanced cancer patients when deciding the initial treatment: a randomized, controlled trial (2012) (42)
Self-expandable metallic stents for patients with recurrent esophageal carcinoma after failure of primary chemoradiotherapy. (2001) (41)
Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. (2000) (41)
Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. (2006) (40)
KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2016) (40)
Three novel single nucleotide polymorphisms in UGT1A9. (2003) (40)
Chemoradiotherapy for esophageal cancer: current status and perspectives (2004) (40)
NARROW‐BAND IMAGING COMBINED WITH MAGNIFIED ENDOSCOPY FOR CANCER AT THE HEAD AND NECK REGION (2005) (39)
Recurrence after endoscopic mucosal resection for superficial esophageal cancer. (2000) (39)
A newly developed bipolar-current needle-knife for endoscopic submucosal dissection of large colorectal tumors. (2006) (39)
Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I–II1, diffuse large B‐cell lymphoma of the stomach (2005) (38)
Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. (2010) (38)
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial (2021) (38)
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer (2018) (38)
Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. (2003) (37)
The role of chemotherapy in the current treatment of gastric cancer (2002) (37)
An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. (1991) (36)
Additional surgery for non-curative resection after endoscopic submucosal dissection for gastric cancer: a retrospective analysis of 200 cases (2017) (36)
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial (2013) (36)
Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. (2016) (35)
Genetic polymorphisms of UGT1A6 in a Japanese population. (2005) (35)
Three novel single nucleotide polymorphisms in UGT1A10. (2002) (35)
Nonplatinum‐based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma (2008) (35)
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. (2004) (34)
Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer (2000) (34)
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer (2016) (34)
Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients (2012) (33)
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. (2011) (33)
Phase I study of olaratumab in Japanese patients with advanced solid tumors (2014) (32)
Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit. (2004) (32)
Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma (2016) (32)
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407) (2016) (32)
A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) (2014) (32)
Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407) (2017) (31)
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839) (2003) (31)
Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. (2007) (31)
Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB). (2013) (31)
Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. (2019) (31)
EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. (2010) (31)
Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A) (2017) (31)
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (2017) (31)
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors (2016) (30)
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer (2019) (30)
Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. (1996) (30)
Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival. (2016) (30)
Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. (2012) (29)
A novel gene–protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity (2015) (29)
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study (2001) (29)
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis (2000) (29)
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors (2014) (28)
Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). (2009) (28)
Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. (2006) (28)
Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models (2015) (28)
Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population (2007) (28)
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. (2005) (28)
Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese (2009) (28)
Epstein–Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B‐cell lymphoma (2006) (28)
Peroral pancreatoscopy for the diagnosis of pancreatic diseases. (1998) (28)
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors (2012) (28)
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors (2009) (28)
Primary squamous cell carcinoma of the stomach: a case report with a review of Japanese and Western literature. (1999) (28)
Routine endoscopy using electronic endoscopes for gastric cancer diagnosis: retrospective study of inconsistencies between endoscopic and biopsy diagnoses. (2001) (27)
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial. (2020) (27)
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery (2016) (27)
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. (2008) (27)
Fluorescent diagnosis of experimental gastric cancer using a tumor-localizing photosensitizer. (1997) (26)
Streptococcus milleri infection and pericardial abscess associated with esophageal carcinoma: report of two cases. (1999) (26)
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm (2017) (26)
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study (2012) (26)
Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients (2013) (25)
FUNCTIONAL ANALYSIS OF SIX HUMAN ARYL HYDROCARBON RECEPTOR VARIANTS IN A JAPANESE POPULATION (2005) (25)
Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. (2015) (25)
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases (2011) (25)
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer (2015) (25)
Growth patterns and genetic changes of colorectal carcinoma. (1998) (25)
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial) (2015) (25)
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients (2008) (24)
Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer (2016) (24)
Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? (2012) (24)
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. (2015) (24)
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer (2013) (24)
Genetic Variations and Haplotype Structures of the ABCB1 Gene in a Japanese Population: An Expanded Haplotype Block Covering the Distal Promoter Region, and Associated Ethnic Differences (2006) (24)
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer (2013) (24)
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 (2013) (23)
Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs . Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis ( JCOG 0106 ) (2013) (23)
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. (2012) (23)
Artificially Induced Epithelial-Mesenchymal Transition in Surgical Subjects: Its Implications in Clinical and Basic Cancer Research (2011) (23)
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer (2012) (23)
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). (2015) (23)
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. (2020) (23)
Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma (2017) (23)
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604) (2015) (23)
Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients† (2014) (23)
Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. (2016) (23)
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908) (2005) (22)
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer]. (2006) (22)
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial (2017) (22)
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors (2012) (21)
Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma. (2011) (21)
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer (2014) (21)
Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). (2003) (21)
Verrucous carcinoma of the esophagus completely resected by endoscopy (2000) (21)
Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer. (2016) (21)
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer (2021) (21)
7BA Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the Phase III ToGA trial (2009) (21)
Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population. (2005) (20)
Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing. (2011) (20)
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. (2012) (20)
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (2018) (20)
Diagnostic utility of endoscopic ultrasonography for preoperative rectal cancer staging estimation. (1996) (20)
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. (2016) (20)
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial. (2016) (19)
Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers. (2011) (19)
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial. (2008) (19)
Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. (2010) (19)
Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population. (2003) (19)
Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study (2003) (19)
NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis (2017) (19)
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey (2003) (19)
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. (2016) (19)
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. (2012) (18)
Epidermoid metaplasia of the esophagus: endoscopic feature and differential diagnosis. (2011) (18)
Implantation of self-expanding metallic stent for patients with malignant stricture after failure of definitive chemoradiotherapy for T3 or T4 esophageal squamous cell carcinomas. (2002) (18)
A laterally-spreading tumor in a colonic interposition treated by endoscopic submucosal dissection. (2010) (18)
Impaired mental health among the bereaved spouses of cancer patients (2013) (18)
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice (2001) (18)
Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial. (2020) (18)
Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study (2002) (18)
Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. (2007) (18)
Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). (2010) (17)
Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. (2011) (17)
Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors (2016) (17)
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis (2020) (17)
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy (2019) (17)
Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). (2016) (17)
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial) (2011) (17)
Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma (2019) (16)
Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts (2019) (16)
Carcinoma coexisting with esophageal leiomyoma. (2002) (16)
Clinicopathological studies on coexisting gastric malignant lymphoma and gastric adenocarcinoma: report of four cases and review of the Japanese literature. (1997) (16)
Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies. (2012) (16)
SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors (2021) (16)
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites (2018) (16)
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups. (2015) (16)
Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer (2017) (16)
Phase I trial of chemoradiotherapy with the combination of S‐1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck (2011) (16)
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer (2013) (16)
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer (2017) (16)
Clinical significance of magnetic resonance cholangiopancreatography for the diagnosis of cystic tumor of the pancreas compared with endoscopic retrograde cholangiopancreatography and computed tomography. (1999) (16)
Psychological states and coping strategies after bereavement among spouses of cancer patients: a quantitative study in Japan (2012) (15)
P-0111PERTUZUMAB, TRASTUZUMAB AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER: AN INTERNATIONAL PHASE III STUDY (JACOB) (2013) (15)
Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients (2013) (15)
Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer. (2016) (15)
Diagnostic findings in endoscopic screening of superficial colorectal neoplasia: results from a prospective study. (1998) (15)
Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer (2020) (15)
Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials (2000) (15)
Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma (2017) (15)
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). (2003) (14)
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503. (2018) (14)
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. (2007) (14)
Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. (2009) (14)
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. (2014) (14)
Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. (2017) (14)
Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303) (2017) (14)
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer (2008) (14)
Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. (2016) (14)
A Micro-Vascular Architecture with NBI Colonoscopy Is Useful to Predict Invasiveness and Allow Patients to Select for Endoscopic Resection Or Surgical Resection (2007) (14)
Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. (2007) (13)
Computer-Assisted Analysis of Biopsy Specimen Microvessels Predicts the Outcome of Esophageal Cancers Treated with Chemoradiotherapy (2006) (13)
Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS). (2006) (13)
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). (2016) (13)
Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study (2012) (13)
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors (2015) (13)
Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial. (2018) (13)
An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). (2015) (12)
Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer (2001) (12)
A phase I study of the human anti‐activin receptor‐like kinase 1 antibody PF‐03446962 in Asian patients with advanced solid tumors (2016) (12)
TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial. (2015) (12)
Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. (2007) (12)
Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912. (2010) (11)
Diverse eastern and Western approaches to the management of gastric cancer. (2007) (11)
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies (2012) (11)
Chemotherapy and chemoradiotherapy for esophageal cancer. (1998) (11)
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (2019) (11)
A phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410). (2002) (11)
Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results (2008) (11)
Does Daily Alcohol and/or Cigarette Consumption Cause Low-grade Dysplasia, a Precursor of Esophageal Squamous Cell Carcinoma? (2008) (11)
A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial (2016) (11)
Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030). (2016) (10)
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer (2003) (10)
Small cell carcinoma of the esophagus with an esophago-mediastinal fistula successfully treated by chemoradiation therapy and intubation: a case report. (1993) (10)
Integrated safety summary for trifluridine/tipiracil (TAS-102) (2018) (10)
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials (2018) (10)
BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (2020) (10)
LBA24Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration (2017) (10)
Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial. (2015) (10)
Overview of adjuvant therapy for resected gastric cancer: differences in Japan and the United States. (2005) (10)
A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies (2005) (10)
Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy (2013) (10)
A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin. (2000) (9)
Phase II clinical study of STI571 in Japanese (Jpn) patients (pts) with malignant gastrointestinal stromal tumors (GIST): results of the B 1201 study. (2004) (9)
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer (2012) (9)
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. (2009) (9)
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer. (2006) (9)
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms (2014) (9)
Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines (2016) (9)
Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2015) (9)
Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population. (2004) (9)
Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. (2016) (9)
Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs (1989) (9)
Expression of Integrin α3 in Gastric and Colorectal Cancers: Its Relation to Wall Contraction and Mode of Invasion (1995) (8)
Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN. (2018) (8)
Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. (2015) (8)
Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602). (2021) (8)
Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07) (2021) (8)
Guidelines for clinical evaluation of anti‐cancer drugs (2021) (8)
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors. (2019) (8)
Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. (2016) (8)
Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. (2010) (8)
Treatment Strategy for Superficial Pharyngeal Squamous Cell Carcinoma Synchronously Combined with Esophageal Cancer (2012) (7)
The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer. (2017) (7)
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (2021) (7)
Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer. (2016) (7)
Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. (2013) (7)
Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma (2018) (7)
A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer (2008) (7)
Exposure–response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer (2018) (7)
Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method (2015) (7)
Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy (2000) (7)
Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer. (2011) (7)
Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect (2014) (7)
Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation. (2017) (7)
Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? (2001) (7)
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. (2010) (7)
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (7)
Macroscopic typing with wall stricture sign may reflect tumor behaviors of advanced colorectal cancers (2001) (7)
[Globalization of clinical trials]. (2003) (7)
1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC) (2020) (7)
A pilot study of post-operative radiotherapy with concurrent chemotherapy for high-risk squamous cell carcinoma of the cervical esophagus. (2011) (7)
O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma (2020) (7)
Gastrointestinal tumors, non-colorectal (2012) (6)
Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib (2017) (6)
The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC). (2014) (6)
A randomized, multicenter, double-blind, placebo (PBO)-controlled phase III study of paclitaxel (PTX) with or without ramucirumab (IMC-1121B; RAM) in patients (pts) with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum (PLT) and fluoropyrimidine (2012) (6)
[Salvage operation for esophageal cancer after radical chemoradiotherapy]. (2002) (6)
A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906) (2007) (6)
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. (2012) (6)
A phase I study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer. (2015) (6)
Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. (2019) (6)
KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer. (2018) (6)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two (2017) (6)
Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation (2017) (6)
Endoscopic submucosal dissection using a new scissors-type electrosurgical knife: a first-in-human feasibility study (2014) (6)
Pembrolizumab (MK-3475) plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer: Preliminary safety data from KEYNOTE-059. (2016) (6)
638PTwo year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07) (2017) (6)
A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer. (2017) (5)
Ramucirumab for gastric cancer (2015) (5)
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer (2019) (5)
2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (5)
RECOURSE trial: Performance status at discontinuation in patients receiving trifluridine/tipiracil (TAS-102) (2016) (5)
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy (2007) (5)
The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01). (2015) (5)
O2-11-5Phase II Study of Nivolumab (ONO-4538/BMS-936558) for Esophageal Cancer: Clinical activity by PD-L1 expression analysis (2016) (4)
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial (2022) (4)
Advanced esophageal cancer with esophago-bronchial fistula successfully treated by chemoradiation therapy with additional endoscopic resection: a case report. (2002) (4)
O-0012 Prognostic Factors of Overall Survival (OS) in Previously Treated Advanced Gastric Cancer (AGC): Analysis of the Phase 3 Granite-1 Trial (2012) (4)
Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma (2019) (4)
[Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages]. (1995) (4)
Abstract A260: A phase 1 study of sorafenib (BAY 43‐9006) in combination with S‐1 plus cisplatin in patients with advanced gastric cancer (2009) (4)
The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries. (2013) (4)
Regional differences in patient (pt) characteristics of AVAGAST: An exploratory comparison in chemotherapy plus placebo (PL) arm between Japanese (JPN) and the rest of the world (ROW) pts. (2012) (4)
Non-surgical treatment for localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Preliminary results of a multicenter prospective study in Japan (2004) (4)
Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors. (2012) (4)
1415 POSTER Blood Plasma VEGFA Analysis in the AVAGAST Randomized Study of First-line Bevacizumab (bev) + Capecitabine/Cisplatin (cape/cis) in Patients (pts) With Advanced Gastric Cancer (AGC) (2011) (4)
Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics). (2015) (4)
The latest advances in chemotherapy for gastrointestinal cancers (2003) (4)
A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors. (2011) (4)
[Latest progress on chemotherapy for advanced gastric cancer]. (2000) (4)
Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo. (2017) (4)
PD-025RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment (2016) (4)
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study. (2016) (4)
S1496: Comparison of Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) for Large Squamous Cell Carcinoma of the Esophagus (2010) (4)
Therapeutic landscape and future direction of metastatic colorectal cancer (2023) (4)
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study. (2018) (4)
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors (2016) (4)
Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503). (2020) (4)
Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. (2020) (4)
Accuracy of Capillary Pattern Classification Using NBI Magnification for Diagnosis of Colorectal Lesions (2008) (4)
Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs (2016) (4)
Response of the primary lesion in gastric cancer to chemotherapeutic trials (1998) (4)
Characterization of the large‐scale Japanese patient‐derived xenograft (J‐PDX) library (2021) (4)
PRELIMINARY RESULTS OF THE PHASE II CLINICAL TRIAL OF IMATINIB MESYLATE FOR ADVANCED GASTROINTESTINAL STROMAL TUMORS IN JAPAN (2004) (3)
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma (2017) (3)
Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis. (2020) (3)
6099 POSTER The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumour Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC) (2011) (3)
Endoscopic Mucosal Resection (EMR) and Photodynamaic Therapy (PDT) As Curative Salvage Treatments for Local Failure After Definitive Chemoradiotherapy (CRT) for Esophageal Cancer (EC) (2007) (3)
A Case of Descending Necrotizing MediastinitisPenetrating to the Esophagus (2010) (3)
Tumor response and symptom palliation from RAINBOW, a phase 3 trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer. (2020) (3)
Combination of endoscopic mucosal resection and chemoradiotherapy as a nonsurgical treatments for patients with clinical stage I esophageal squamous cell carcinoma (2007) (3)
Clinical Cancer esearch cer Therapy : Clinical se I Study of NK 012 , a Novel SN-38 – Incorporating Micellar R oparticle , in Adult Patients with Solid Tumors (2010) (3)
Clinicopathological, endoscopic, and molecular characteristics of the “skirt” – a new entity of lesions at the margin of laterally spreading tumors (2016) (3)
Gastropexy Reduces Severe Adverse Events After Percutaneous Endoscopic Gastrostomy (PEG) (2007) (3)
Prognostic factors for PFS in patients with advanced gastric cancer: Using the data from JCOG9912 study. (2011) (3)
A Phase II Study of Irinotecan in Combination with 120-h Infusion of 5-Fluorouracil in Patients with Metastatic Colorectal Carcinoma : Japan Clinical Oncology Group Study ( JCOG 9703 ) (2002) (3)
Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial. (2016) (3)
Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up. (2021) (3)
Endoscopic mucosal resection for early adenocarcinoma arising in Barrett's esophagus (2001) (3)
Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials (2017) (3)
[Current Status and Future Perspectives of SCRUM-Japan]. (2017) (3)
Verrucous carcinoma of the esophagus completely resected by endoscopy. (2000) (3)
Peritonitis related to percutaneous endoscopic gastrostomy using the direct method for cancer patients (2015) (3)
Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC). (2011) (3)
423 POSTER Phase I dose escalation study of NK012, polymer micelle of irinotecan metabolite SN-38, in patients with advanced cancer (2008) (3)
Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study. (2020) (3)
Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials (2015) (3)
Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer. (2018) (3)
Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2). (2014) (3)
Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial (2016) (3)
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (3)
Causal relationships between esophageal squamous cell carcinoma and nephrotic syndrome. (2009) (3)
The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)—GI-SCREEN 2013-01-CRC sub-study. (2016) (3)
3032 POSTER Health-related Quality of Life in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Cancer With High HER2 Expression Levels – Exploratory Analysis of the Phase III ToGA Study (2011) (2)
Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study. (2016) (2)
Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102) (2016) (2)
213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors (2014) (2)
Clinicopathological features of program death ligand-1 (PD-L1) expression with tumor-infiltrating lymphocytes (TILs), mismatch repair (MMR) and Epstein-Barr virus (EBV) status in a large cohort of gastric cancer. (2016) (2)
6005 ORAL A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC) (2011) (2)
Time to grade ≥3 adverse events in pts receiving trifluridine/tipiracil (TAS-102). (2017) (2)
Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. (2013) (2)
An early phase II study of etoposide (VP-16) in advanced gastric cancer. (1996) (2)
6121 POSTER Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC) (2011) (2)
Abstract 29: Phase I study of intravenous PI3K inhibitor BAY 80-6946 in Japanese subjects. (2013) (2)
516PA Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410) (2017) (2)
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies (2020) (2)
Treatment outcome and recovery from peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (JFMC41-1001-C2: JOIN Trial). (2017) (2)
Case Series of Endoscopic Submucosal Dissection (ESD) for Early Remnant Gastric Cancer After Subtotal Gastrectomy (2009) (2)
A phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: the Japan Clinical Oncology Group trial (JCOG0109). (2004) (2)
A phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: the Japan Clinical Oncology Group trial (JCOG0109) (2004) (2)
TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy. (2011) (2)
Analysis of hematologic adverse events (HeAEs) in trifluridine/tipiracil (FTD/TPI)-treated patients (pts) with or without renal/hepatic impairment (RI/HI): Pooled safety analyses from TAGS and RECOURSE. (2020) (2)
Nonsurgical treatments for submucosal esophageal squamous cell carcinomas (2007) (2)
Phase I Clinical and Pharmacokinetic Study of RAD 001 ( Everolimus ) Administered Daily to Japanese Patients with Advanced Solid Tumors (2009) (2)
Abstract 211: Sulfasalazine (SSZ) works cancer stem-like cells (CSCs) via inhibiting xCT signal pathway: Phase 1 study in patients with gastric cancer (EPOC 1205) (2014) (2)
Comparison between fluorescent images of gastric cancer with an endoscopic autofluorescence imaging system and the histological findings (1998) (2)
The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC). (2015) (2)
An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial. (2016) (2)
Tolerability study of adjuvant modified FOLFOX6 treatment in curatively resected stage II/III colon cancer (JFMC41-1001-C2: JOIN trial). (2014) (2)
Prognostic factors in Japanese patients with advanced gastric cancer using the data from JCOG9912 study. (2011) (2)
Depressed-type (0-IIc) colorectal neoplasm in patients with family history of first-degree relatives with colorectal cancer: A cross-sectional study. (2006) (2)
Relationship between serum HER2 level and histologic HER2 status in patients with advanced/recurrent gastric cancer. (2012) (2)
An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors. (2018) (2)
2150 Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (2)
M1496: Photodynamic Therapy for Local Failure After Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (2010) (2)
Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data. (2022) (2)
Abstract B159: Phase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. (2011) (2)
Prophylactic use of oral dexamethasone (DEX) to alleviate fatigue during regorafenib (REG) treatment for patients with advanced colorectal cancer (aCRC). (2015) (1)
The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit. (2018) (1)
Allergic reactions (ARs) induced by FOLFOX4 treatment in colorectal cancer: A comparative analysis between Asian and Western patients (pts). (2011) (1)
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience (2015) (1)
QTWIST analysis in the RECOURSE trial. (2017) (1)
Long-Term Outcomes of Patients with Superficial Esophageal Squamous Cell Carcinoma After Endoscopic Mucosal Resection (EMR) (2008) (1)
Abstract 1669: Preclinical efficacy of Sym004, novel anti-EGFR antibody, in esophageal squamous cell carcinoma cell lines (2015) (1)
A phase I study of NC-6004, a micellar formulation of cisplatin, in combination with gemcitabine in Japanese patients with advanced solid tumors. (2016) (1)
Efficacy of surgery after successful chemotherapy for advanced gastric cancer (1998) (1)
New approach for assessment of potential ethnic differences in parallel phase l/ll studies in the United States and Asia. (2010) (1)
Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A). (2015) (1)
A model chemosensitivity test examining apoptosis in small specimens of gastric cancer (2000) (1)
Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data. (2015) (1)
SO-25 A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701) (2020) (1)
Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC). (2019) (1)
Current Status of Chemotherapy for Advanced Gastric Cancer and Expectations for Molecular Targeting Therapy (2012) (1)
2116 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE) (2015) (1)
Japanese multicenter phase II study of CHOP followed by radiotherapy (RT) in stage I-II1 diffuse large B-cell lymphoma (DLBCL) of the stomach. (2004) (1)
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (2019) (1)
Future perspectives of chemotherapy for advanced gastric cancer (2009) (1)
W1883 Phase II Study of Photodynamic Therapy (PDT) for Local Failure After Chemoradiotherapy (CRT) in Patients With Esophageal Squamous Cell Carcinoma (ESCC) (2010) (1)
Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study. (2013) (1)
Abstract 34: A phase I study of a p70S6 kinase inhibitor (LY2584702) in patients (pts) with solid tumors. (2013) (1)
Efficacy and safety of ramucirumab containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. (2018) (1)
Gastrointestinal tumors, colorectal (2012) (1)
KEYNOTE-061: pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer. (2018) (1)
Meaningful changes in quality of life (QoL) in patients with gastric cancer: Exploratory analyses from RAINBOW and REGARD. (2017) (1)
2107 Safety and efficacy on TAS-102 monotherapy in patients with metastatic colorectal cancer according to previous regorafenib (2015) (1)
Oncology and public health (2012) (1)
Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC). (2018) (1)
Effect of sulfasalazine (SSZ) on cancer stem-like cells (CSCs) via inhibiting xCT signal pathway: Phase 1 study in patients with gastric cancer (EPOC 1205). (2014) (1)
Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD). (2013) (1)
Joint United States of America (USA)/Japan study of UFT (uracil and tegafur) plus leucovorin (LV) in patients (pts) with metastatic colorectal cancer (CRC) (2001) (1)
Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD. (2017) (1)
Abstract C6: Phase 1 study of conatumumab (AMG 655), a proapoptotic death receptor‐5 agonist antibody, in Japanese patients with advanced solid tumors (2009) (1)
Successful endosocpic submucosal dissection for esophageal squamous cell carcinoma together with a lipoma. (2011) (1)
PD-017A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE) (2015) (1)
Computed tomography under endoscopic retrograde pancreatography (ERP-CT) to investigate the drainage area of the pancreatic head. (1999) (1)
2301 Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538) in Patients with Esophageal Cancer: Preliminary Report (2015) (1)
Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study. (2020) (1)
Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC): A phase I/II study (2004) (1)
O1-3-1Comparison between NAC-S and CRT in overall survival for patients with esophageal squamous cell carcinoma (JCOG1406-A) (2015) (1)
Abstract CT213: Arctigenin, an antiausterity agent shows high safety and promising clinical response in phase I clinical trial in patient with gemcitabine-refractory pancreatic cancer (2014) (1)
Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Köhne model (Km). (2012) (1)
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: The NCCHE experience. (2015) (1)
The Differential Diagnosis of Malignant Lymphoma and Reactive Lymphoreticular Hyperplasia of the Stomach Using Endoscopic Ultrasonography (1994) (1)
3061 POSTER Phase I/II study of novel oral fluoropyrimidine S-1 in combination with oxaliplatin (SOX) as first-line chemotherapy for metastatic colorectal cancer (mCRC) (2007) (1)
Effect of number of prior lines versus prior regimens in pts receiving trifluridine/tipiracil (TAS-102). (2017) (1)
6063 Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC) (2009) (1)
Clinicopathological features of program death ligand-1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. (2017) (1)
626PPROGNOSTIC IMPACT OF HER2, EGFR, AND C-MET STATUS ON OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS TREATED WITH STANDARD CHEMOTHERAPY WITHOUT TRASTUZUMAB IN A FIRST-LINE TREATMENT: A JAPANESE MULTICENTER COLLABORATIVE RETROSPECTIVE STUDY. (2014) (1)
Abstract 27: A phase I study of MEK inhibitor BAY 86-9766 in Japanese patients with advanced or reflactory solid tumors. (2013) (1)
428 POSTER A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors (2008) (1)
300MO Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population (2020) (1)
The final results of a multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201) (2016) (1)
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410. (2016) (1)
Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC) (2016) (1)
Drainage area of the head of the pancreas by computed tomography under endoscopic retrograde pancreatography (ERP-CT). (1999) (1)
Feasibility Study of a New Percutaneous Endoscopic Gastrostomy (PEG) Procedure, the “Direct IDEAL PEG”, in Patients with Advanced Head and Neck Cancer Or Esophageal Cancer (2008) (1)
Safety analysis of FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients. (2010) (1)
LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC) (2016) (1)
IS4. Trials in Progress (2012) (1)
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution. (2012) (1)
Abstract B98: AUY922, a novel HSP90 inhibitor: Final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies. (2011) (1)
Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer (2016) (1)
Is hyperplastic rectal polyp (HRP) useful as a marker for colorectal cancer in low risk patients (1998) (1)
IS3. Gastric Cancer (2012) (0)
[Current status of combined modality therapy for esophageal cancer: from the standpoint of medical oncology]. (1998) (0)
401MO OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial (2020) (0)
415P Prognostic effect of postoperative serum carcinoembryonic antigen (CEA) combined with T4 versus T3 tumors in patients with high-risk stage 2 colon cancer: ACHIEVE-2 phase III randomized clinical trial (2020) (0)
Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer (2016) (0)
ISY-17-5Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for mCRC (C-TASK FORCE) (2016) (0)
8539 Induction chemotherapy with docetaxel, cisplatin and S-1 (TPS) followed by proton therapy concurrent with cisplatin in the patients with T4 nasal cavity cancer (2009) (0)
Age, gender, and performance status effects on efficacy of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer: Phase III ACHIEVE trial as part of the IDEA collaboration. (2018) (0)
Minute invasive squamous cell carcinoma of the esophagus associated with head and neck cancer: a case report. (1999) (0)
ISY4-4What is a useful biomarker for advanced gastric cancer (AGC)? (2015) (0)
“Para‐lesional” Saline Injection Method for Assessment of Small Gastric Cancers by Endoscopic Ultrasonography (1996) (0)
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant (2023) (0)
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program. (2023) (0)
328 INVITED Lessions From Global Clinical Trials for Gastric Cancer – Are They Steps Ahead? (2011) (0)
Endoscopic salvage treatment for local failure after definitive chemoradiotherapy (CRT) for esophageal cancer (EC) (2005) (0)
Correlation Between the Depth of Invasion and Hardness of Resected Gastric Carcinoma Specimens Using a New Ultrasound Tactile Sensor (1998) (0)
Chemotherapy for Advanced Unresectable Gastric Cancer (2005) (0)
Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit (2013) (0)
2328 Outcomes in 44 Patients with metastatic esophageal squamous cell carcinoma treated in phase 1 trials: the NCCHE Experience (2015) (0)
Retrospective Analysis of Endoscopic Balloon Dilatation (EBD) for Benign Fibrotic Strictures After Curative Non-Surgical Treatment for Esophageal Cancer (EC) (2009) (0)
O-16 Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and ACHIEVE-2 trials (2020) (0)
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma (2017) (0)
Abstract LB-284: Toward clinical sequencing: analysis of FFPE samples of 121 gastric cancer by a benchtop sequencer (2014) (0)
T1426: Evaluation of Complications Related to Therapeutic Colonoscopy Using Bipolar Snare (2010) (0)
Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis. (2020) (0)
Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method (2015) (0)
The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer. (2016) (0)
DJS-3 Utilizing real-world data as an external control for new drug approval in molecular subtype: experience in SCRUM-Japan Registry (2022) (0)
Association of a novel polymorphism G-133C of thymidylate synthase (TYMS) gene with 5-FU-related severe diarrhea in Japanese patients with colorectal cancer (2007) (0)
Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. (2021) (0)
[Present status of chemotherapy for colorectal cancer in countries outside of Japan]. (2003) (0)
[Chemotherapy with molecular targeting agents for colorectal cancer]. (2012) (0)
2297 Clinical features of exceptional responders with unresectable and metastatic gastric cancers by palliative chemotherapy: A long follow-up (2015) (0)
Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients. (2016) (0)
[Concurrent chemoradiotherapy for T4 and/or M1 LYM squamous cell carcinoma of the esophagus]. (2000) (0)
Definitive chemoradiotherapy (CRT) for elderly patients (pts) with thoracic squamous cell carcinoma (SCC) of the esophagus (2005) (0)
Salvage photodynamic therapy (PDT) for locoregional failure after definitive chemoradiotherapy (CRT) for esophageal cancer (EC). (2004) (0)
Impact of high-risk features on disease-free survival (DFS) in patients (pts) with high-risk stage II colon cancer (CC) in ACHIEVE-2 trial as part of the IDEA collaboration. (2020) (0)
Phase 1B Study of a Novel Oral Ppar-Gamma Agonist, Efatutazone in Combination with Folfiri in Japanese Patients with Metastatic Colorectal Cancer who Failed the First-Line Therapy (2012) (0)
' s response to reviews Title : Construction of possible integrated predictive index based on EGFR and ANXA 3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method (2015) (0)
Comparative sequence analysis between primary colorectal cancer, metastasis and recurrent metastasis after adjuvant FOLFOX chemotherapy (2016) (0)
Post-Marketing Survey of Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: Interim Report of 3,005 Patients (2012) (0)
Bevacizumab in Combination With Chemotherapy as First-LineTherapyinAdvancedGastricCancer:ABiomarker EvaluationFromtheAVAGASTRandomizedPhaseIIITrial (2012) (0)
OS1. gastric cancer (2012) (0)
Long-Term T oxicity A fter D efinitive C hemoradiotherap y f or Squamous C ell C arcinoma o f t he T horacic E sophagus (2003) (0)
A case of duodenal carcinoid tumor completely resected by endoscopic mucosal resection (1998) (0)
Clinical Outcomes of Patients Resulted in Bleeding Associated with Therapeutic Colonoscopies (2006) (0)
723 POSTER A phase I dose-escalation study of RAD001 administered daily to Japanese patients with advanced solid tumors (2007) (0)
Supplementary Material for: Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials (2017) (0)
Non-surgical treatment for localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Preliminary results of a multicenter prospective study in Japan. (2004) (0)
Treatment for locally advanced esophageal carcinoma complicated by fistulas: Case report (1996) (0)
Chronological change in chemo-biologic therapy, gastrointestinal cancer. (2017) (0)
ASTUDY ON ENDOSCOPIC FINDINGS OF MUCINOUS CARCINOMA OF TIIE STOMACH (1999) (0)
Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005 (2006) (0)
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial (2022) (0)
Phase 1 Study of the Selective Akt Inhibitor MK-2206 in Japanese Patients with Advanced Solid Tumors (2012) (0)
The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer. (2011) (0)
Definitive C hemoradiotherap y f or T 4 a nd/or M 1 L ymph N ode Squamous C ell C arcinoma o f t he E sophagus (1999) (0)
CLINICAL USEFULLNESS OF ENDOSCOPIC CLIPPING FOR DETERMINATION OF THE SURGICAL RESECTION LINE FOR EARLY GASTRIC CANCER (1999) (0)
Narrow Band Imaging System Could Be a Promising Tool to Detect a Stage 0 Head and Neck Cancer: New Enlightenment to the Endoscopists (2004) (0)
[Current status and issues in early & exploratory oncology clinical trials in Japan]. (2015) (0)
[New drugs for unresectable or recurrent gastric cancer--paclitaxel and docetaxel]. (2001) (0)
Association of postoperative serum carcinoembryonic antigen (CEA) with disease-free survival in patients with stage III colon cancer: ACHIEVE phase III randomized clinical trial. (2020) (0)
101 PIK3CA mutation-targeting compounds analyses using NCI60 cell line panel (2014) (0)
New Device for Percutaneous Endoscopic Gastrostomy (PEG) Feeding Using Semi-Solid Food (2005) (0)
Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2016) (0)
JS4-5Activity for new oncology agent development in the clinical trial center (2015) (0)
A Prospective Study for Differential Diagnosis of Gastric Small Depressive Lesions By Narrow Band Imaging (NBI) Combined with Magnifying Endoscopy (2009) (0)
Efficacy of systemic chemotherapy (CT) for the patients (pts) with unresectable liver metastasis (LM) of colorectal cancer (CRC). (2006) (0)
[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy]. (2009) (0)
Phase I I S tudy o f a C ombination o f I rinotecan a nd C isplatin Against M etastatic G astric C ancer (1999) (0)
Long-term toxicity and survival of definitive chemoradiotherapy (CRT) in patients (pts) with T4/M1LYM esophageal carcinoma. (2004) (0)
New drugs for colorectal cancer based on Japanese experience. (2000) (0)
Evaluation of heterogeneities in baseline risks and treatment effects among hospitals: Additional result of JCOG9912 phase III trial for advanced gastric cancer (2008) (0)
2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD and RAINBOW) (2015) (0)
New Feeding Management for Percutaneous Endoscopic Gastrostomy (PEG) Using Semi-Solid Food with a New Device, the ‘CP-PEG Connector’ (2007) (0)
Author's response to reviews Title:Clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer Authors: (2015) (0)
A phase I study of EMD 525797, a novel humanized monoclonal antibody to human integrin alpha v, in Japanese patients with solid tumor. (2017) (0)
Title Report on the use of non-clinical studies in the regulatoryevaluation of oncology drugs (2019) (0)
Usefulness of NBI to Distinguish Between Non-Neoplastic and Neoplastic Lesions Without the Influence of Performer Whether He Is Expert Or Not (2007) (0)
S1557: Efficacy of Capillary Pattern Type IIIA/IIIB by Magnifying Narrow Band Imaging for Estimating Depth of Invasion of Early Colorectal Neoplasms (2010) (0)
180P Clinical outcome of anal squamous cell carcinoma treated with chemoradiotherapy with 5-fluorouracil plus mitomycin C (2016) (0)
The Lack of HER-2/neu Oncogene Amplification in Colorectal Malignancies (2003) (0)
Japanese multicenter phase II study of CHOP followed by radiotherapy (RT) in stage I-II1 diffuse large B-cell lymphoma (DLBCL) of the stomach (2004) (0)
Additional file 1: Figure S1. of Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer (2016) (0)
Abstract 2208: Detection of somatic mutations and gene amplifications using amplicon sequencing with biopsy samples from patients with advanced gastric cancer (2014) (0)
Clinicopathological differences between metachronous and synchronous multiple colorectal carcinomas (2000) (0)
Abstract 2813: Clinical impact of immune microenvironment according to intratumoral locations of esophageal squamous cell carcinoma (2019) (0)
Comprehensive molecular profiling of advanced gastric cancer (AGC) using NGS and immunohistochemistry (IHC). (2014) (0)
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium:1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents antibody therapy; introduction]. (2012) (0)
PSY1. new anti-cancer drug development in japan and its new prospect (2012) (0)
Final report of post-marketing survey of panitumumab in Japanese patients with unresectable advanced or recurrent colorectal cancer. (2013) (0)
Tu1617 Long-Term Result of Photodynamic Therapy (PDT) As a Salvage Treatment for Patients With Local Failure After Definitive Chemoradiotherapy (CRT) for Esophageal Squamous Cell Carcinoma (ESCC) (2009) (0)
6109 POSTER Difference in Overall Survival in Colorectal Cancer Patients With the KRas P.G13D and Other KRas Mutations After the Failure of 5-fluorouracil, Oxaliplatin, and Irinotecan (2011) (0)
Clinical Results of Definitive Chemoradiotherapy with Three-dimensional Conformal Radiotherapy and Selective Salvage Treatment for Stage II-III (non-T4) Squamous Cell Carcinoma of the Thoracic Esophagus (2010) (0)
Neutrophil-to-lymphocyte ratio as a prognostic factor and its relationship to patient (pt) outcomes in the RAINBOW trial. (2020) (0)
The IDEA Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX Regimen for Patients with Stage III Colon Cancer: Current Status. (2014) (0)
O3-6-6Gastrointestinal perforation and fistula formation in colorectal cancer patients during regorafenib treatment (2015) (0)
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (0)
Non-biopsy techniques for qualitative diagnosis of colorectal tumor (1998) (0)
Chemoradiotherapy for squamous cell carcinoma of the anus: the same histology but different story? (2007) (0)
Phase I/II trial of chemoradiotherapy concurrent with S-1 and cisplatin in patients with clinical stage II/III esophageal carcinoma: Results of the Japan Clinical Oncology Group study JCOG 0604. (2014) (0)
Computer-Assisted Analysis of Biopsy SpecimenMicrovessels Predicts the Outcome of Esophageal Cancers Treatedwith Chemoradiotherapy (2006) (0)
Clinicopathological characteristics and impact on efficacy of three versus six months of adjuvant chemotherapy in early-onset colon cancer: ACHIEVE and ACHIEVE-2 trials. (2021) (0)
O1-13-3OUTCOMES IN 50 PATIENTS WITH ADVANCED GASTRIC CANCER TREATED IN PHASE I TRIALS: THE NCCHE EXPERIENCE (2014) (0)
Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS. (2019) (0)
6107 A pitfall of KRAS sequencing using a small amount of DNA extracted from formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues (2009) (0)
Guideline for clinical safety data management in Japan Clinical Oncology Group (JCOG) (version 4) (2001) (0)
Analysis of esophagogastric cancer patients enrolled in National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials. (2015) (0)
[Retrospective analysis of antiemetic effect in patients receiving cisplatin]. (2011) (0)
A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 - Trial in progress. (2018) (0)
A long-term survivor of metastatic gastric cancer treated by chemotherapy: case report. (1991) (0)
1152PPhase 1 study of HSP105-derived peptide vaccine for patients with advanced esophageal cancer/colo- rectal cancer (2017) (0)
Summaries from the 64th annual meeting of the Japan esophageal society August 31–September 1, 2010, Kurume (2010) (0)
Is gastric cancer producing alpha-fetoprotein highly chemosensitive?; from clinical and molecular biological studies (1995) (0)
Poster abstracts of the 18th Pan Arab Cancer Congress. TUNISIA. April 19-21, 2018. (2018) (0)
ISY-25-4 Activities in new oncology agent development in Japan (2016) (0)
A novel and simple KRAS mutation detection method, FRET-Based Preferential Homoduplex Formation Assay (f-PHFA): Results from a multicenter, clinical evaluation trial. (2012) (0)
465 POSTER Phase I/II study of oxaliplatin (L-OHP) in combination with S-1 (SOX) as first-line therapy for metastatic colorectal cancer (MCRC) (2006) (0)
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy (2019) (0)
O3-8-4Clinicopathological features of PD-L1 expression with MMR, EBV status and cancer genome alterations in MGC (2017) (0)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (0)
New Agent Developments in ‘Early-Stage and Exploratory Clinical Trial Center’ (2012) (0)
A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. (1996) (0)
Abstract 2935: Preclinical efficacy of the p70S6K/AKT dual inhibitor M2698 in combination with trastuzumab in models of gastric cancer (2018) (0)
2158 The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01) (2015) (0)
TREATMENT STRATEGIES FOR ESOPHAGEAL STRICTURE BEFORE OR AFTER CHEMORADIOTHERAPY FOR ADVANCED ESOPHAGEAL CANCER (2004) (0)
Long-term results of salvage endoscopic treatment for patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. (2014) (0)
465 Detection of somatic mutations and gene amplification using Oncomine Cancer Research Panel with biopsy samples from patients with advanced gastric cancer (2015) (0)
Abstract 3280: Phase 1 study of AMG 386, an anti-angiogenic Fc fusion protein targeting angiopoietin-1 and -2, in Japanese patients with advanced solid tumors (2011) (0)
O3-5-1Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors or hepatocellular carcinoma (2016) (0)
6050 Clinical features of interstitial lung disease induced by FOLFOX or FOLFIRI for colorectal cancer (2009) (0)
Sa1608 Radial Incision and Cutting (RIC) Method Is More Effective Than Continued Endoscopic Balloon Dilation (EBD) for Refractory Anastomotic Stricture: A Comparative Study (2012) (0)
[Informed consent in gastric cancer patients treated with chemotherapy]. (2001) (0)
How to detect superficial type of colorectal neoplasms? - From a retrospective and a prospective analyses of endoscopic findings (1995) (0)
S1606: μ-VOIS, A Novel Three-Dimensional Microstructure Imaging System Based on Optical Coherence Tomography (2010) (0)
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites (2018) (0)
μ-Vois, a Novel Three-Dimensional Microstructure Imaging System Using Near-Infrared Beams (2011) (0)
Retrospective Analysis of Radical Incision and Cutting (RIC) for Benign Refractory Stricture After Curative Treatment for Upper Gastrointestinal Carcinomas (2008) (0)
Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma (2019) (0)
Endoscopic Study of Differential Diagnosis between Benign Ulcers and Malignancies with Open Ulcers of the Stomach (1996) (0)
Molecular landscape and prognostic value of HER2 low-expression on metastatic colorectal cancer. (2020) (0)
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study (2016) (0)
Ramucirumab for gastric (2015) (0)
Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC): A phase I/II study. (2004) (0)
Progress of Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma (2012) (0)
WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
Additional file 3: Figure S3. of Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer (2016) (0)
Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population (2022) (0)
Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial. (2017) (0)
The Formation and Analysis of a Test of Listening Comprehension Abilities for High School Students in Japan and South Korea (1998) (0)
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer (2015) (0)
Correction (2014) (0)
[Participation to international registration trials--from the investigator's standpoint]. (2007) (0)
Risk of Metachronous Multiple Intra-Esophageal Carcinomas After Endoscopic Mucosal Resection (EMR) for Esophageal Squamous Cell Carcinoma (ESCC) (2008) (0)
Long-term toxicity and survival of definitive chemoradiotherapy (CRT) in patients (pts) with T4/M1LYM esophageal carcinoma (2004) (0)
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer. (2023) (0)
[Controversies in the treatment of esophageal cancer from the viewpoint of medical oncology]. (2003) (0)
A Randomized, Double-Blind, Phase (PH) III Study of Folfiri Plus Ramucirumab (RAM) or Placebo (PL) in Patients (Patients) with Metastatic Colorectal Carcinoma (MCRC) Progressed During or Following 1st-Line Therapy with Bevacizumab (BEV), Oxaliplatin (OXALI), and a Fluoropyrimidine (FP) (RAISE) (NCT0 (2012) (0)
RECOURSE Study Finds TAS-102 Effective in Colorectal Cancer (2015) (0)
[Correlation between response and survival]. (2000) (0)
[Current topics on molecular targeting drugs for gastric cancer]. (2010) (0)
W1485: Long-Term Outcomes After Endoscopic Resection for Submucosal Invasive Colorectal Cancer (2010) (0)
A STUDY OF DIVERGENT MORPHOLOGY OF THE PANCREATIC DUCT BY COMPUTED TOMOGRAPHY UNDER ENDOSCOPIC RETROGRADE PANCREATOGRAPHY (1996) (0)
Abstract B29: Feasibility of amplicon sequencing using a pan-cancer gene panel with pre-treatment biopsy samples of (Japanese) patients with advanced solid tumors: Analyses of Biopsy Samples for Cancer Genomics (ABC) study. (2013) (0)
Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Atsushi Ohtsu?

Atsushi Ohtsu is affiliated with the following schools:

Seoul National University
Hokkaido University
University of Ulsan College of Medicine
University of Tokyo
Kitasato University
Showa University
Keio University
Hyogo College of Medicine
Juntendo University
Okayama University
Osaka University
Oita University